• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Twist Bioscience Corporation - Common Stock (NQ:TWST)

    152.33 +1.00 (+0.66%)
    Delayed Quote Updated: 9:52 AM EDT, Oct 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Twist Bioscience Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    News headline image
    These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys? ↗
    Forget the "Magnificent Seven" in favor of the "Tremendous Three"? 
    Via The Motley Fool
    News headline image
    Why Twist Bioscience Stock Skyrocketed This Week ↗
    It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
    From Twist Bioscience Corporation
    Via Business Wire
    Twist Bioscience TWST Q2 Fiscal 2026: Revenue Beat Offset by Wider EPS Miss ↗
    Via Chartmill
    News headline image
    Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
    From Twist Bioscience Corporation
    Via Business Wire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Twist Bioscience (TWST) Q3 2026 Earnings Call Transcript ↗
    AI-enabled drug discovery orders drive triple-digit growth as guidance rises. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience Sees AI Drug Discovery Pipeline Expand ↗
    Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discovery and NGS businesses show growth. 
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Twist Bioscience Q3 Earnings Call Highlights ↗
    Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth. The company raised its full-year... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Cathie Wood Is Selling This High-Flying Stock. Is It a Buy? ↗
    Wood's ETFs sell stocks that have had strong runs to pay for other positions. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own ↗
    AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors. ↗
    This synthetic DNA specialist, leveraging silicon chip technology, reported a notable insider sale amid a year of strong share gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors? ↗
    This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million ↗
    This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist (TWST) Q2 2026 Earnings Call Transcript ↗
    Twist (TWST) Q2 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Artificial Intelligence Earnings
    News headline image
    Twist (TWST) Q3 2025 Earnings Transcript ↗
    Twist (TWST) Q3 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience to Present at Upcoming Investor Conferences
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
    From Twist Bioscience Corporation
    Via Business Wire
    News headline image
    Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
    Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia? 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
    From Twist Bioscience Corporation
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.